The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Future role of CAR-T in myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses the future role of chimeric antigen receptor T-cell (CAR-T) therapy in the treatment of multiple myeloma. Prof. Einsele talks on the efficacy and tolerability of CAR-T in heavily pretreated patients, commenting on high response rates and complete response rates, and the potential of CAR-T therapy to be a cure for myeloma if used in earlier settings. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
